Nisa Investment Advisors LLC boosted its holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 16.7% during the third quarter, Holdings Channel reports. The institutional investor owned 21,642 shares of the biopharmaceutical company’s stock after buying an additional 3,098 shares during the period. Nisa Investment Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $8,744,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. First Hawaiian Bank acquired a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth about $1,460,000. Bank of Montreal Can boosted its stake in Regeneron Pharmaceuticals by 27.5% in the 3rd quarter. Bank of Montreal Can now owns 55,397 shares of the biopharmaceutical company’s stock worth $22,383,000 after buying an additional 11,943 shares during the last quarter. Founders Capital Management LLC acquired a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth about $226,000. DNB Asset Management AS acquired a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth about $9,143,000. Finally, Visionary Asset Management Inc. acquired a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth about $231,000. 66.28% of the stock is currently owned by hedge funds and other institutional investors.

A number of analysts have issued reports on REGN shares. ValuEngine raised Regeneron Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, September 6th. BidaskClub raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, September 1st. Leerink Swann raised their price objective on Regeneron Pharmaceuticals from $506.00 to $512.00 and gave the stock an “outperform” rating in a report on Monday, October 1st. Argus raised their price objective on Regeneron Pharmaceuticals from $383.00 to $415.00 and gave the stock a “buy” rating in a report on Monday, July 16th. Finally, UBS Group upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Wednesday, June 27th. Two research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and eight have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $412.19.

Regeneron Pharmaceuticals stock opened at $389.83 on Friday. The stock has a market capitalization of $43.12 billion, a PE ratio of 29.07, a PEG ratio of 1.33 and a beta of 1.12. The company has a current ratio of 3.62, a quick ratio of 2.92 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals Inc has a 12 month low of $281.89 and a 12 month high of $437.90.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, August 2nd. The biopharmaceutical company reported $5.45 EPS for the quarter, beating the consensus estimate of $4.60 by $0.85. The business had revenue of $1.61 billion for the quarter, compared to the consensus estimate of $1.56 billion. Regeneron Pharmaceuticals had a return on equity of 29.30% and a net margin of 25.65%. The company’s revenue was up 9.4% on a year-over-year basis. During the same period last year, the business posted $4.17 EPS. On average, equities analysts forecast that Regeneron Pharmaceuticals Inc will post 19.4 earnings per share for the current fiscal year.

In related news, Director Joseph L. Goldstein sold 2,000 shares of the firm’s stock in a transaction dated Thursday, August 2nd. The stock was sold at an average price of $380.00, for a total transaction of $760,000.00. Following the sale, the director now directly owns 14,000 shares in the company, valued at approximately $5,320,000. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Michael S. Brown sold 1,500 shares of the firm’s stock in a transaction dated Wednesday, August 22nd. The shares were sold at an average price of $380.49, for a total value of $570,735.00. Following the sale, the director now owns 1,500 shares in the company, valued at $570,735. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 112,052 shares of company stock worth $45,411,762. Company insiders own 12.42% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Article: How to Use the New Google Finance Tool

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.